Cover Image

Validation of a blood protein signature for non-small cell lung cancer

CT screening for lung cancer is effective in reducing mortality, but there are areas of concern, including a positive predictive value of 4% and development of interval cancers. A blood test that could manage these limitations would be useful, but development of such tests has been impaired by varia...

Full description

Saved in:
Bibliographic Details
Main Authors: Mehan, Michael R. (Author) , Williams, Stephen A. (Author) , Siegfried, Jill M. (Author) , Bigbee, William L. (Author) , Weissfeld, Joel L. (Author) , Wilson, David O. (Author) , Pass, Harvey I. (Author) , Rom, William N. (Author) , Muley, Thomas (Author) , Meister, Michael (Author) , Franklin, Wilbur (Author) , Miller, York E. (Author) , Brody, Edward N. (Author) , Ostroff, Rachel M. (Author)
Format: Article (Journal)
Language:English
Published: 1 August 2014
In: Clinical proteomics
Year: 2014, Volume: 11
ISSN:1559-0275
DOI:10.1186/1559-0275-11-32
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/1559-0275-11-32
Get full text
Author Notes:Michael R. Mehan, Stephen A. Williams, Jill M. Siegfried, William L. Bigbee, Joel L. Weissfeld, David O. Wilson, Harvey I. Pass, William N. Rom, Thomas Muley, Michael Meister, Wilbur Franklin, York E. Miller, Edward N. Brody and Rachel M. Ostroff
Description
Summary:CT screening for lung cancer is effective in reducing mortality, but there are areas of concern, including a positive predictive value of 4% and development of interval cancers. A blood test that could manage these limitations would be useful, but development of such tests has been impaired by variations in blood collection that may lead to poor reproducibility across populations.
Item Description:Gesehen am 16.02.2021
Physical Description:Online Resource
ISSN:1559-0275
DOI:10.1186/1559-0275-11-32

Similar Items